同花順(300033.SZ):在AIGC方向,建設了自動化構建、驅動、渲染的包括2D、2.5D、3D數字人系統
格隆匯3月29日丨同花順(300033.SZ)於2023年3月27日下午15:00-17:00舉行2022年度業績説明會,“公司是否有在AIGC領域進行研發,進展如何?”,公司表示,在AIGC方向,建設了自動化構建、驅動、渲染的包括2D、2.5D、3D數字人系統,短視頻生成平台整合了自動寫音樂、自動改寫文章、摘要抽取等功能,可以快速生成短視頻;智能寫作系統可以自動寫研報、新聞;代碼生成系統能夠輔助程序員提高代碼效率。相關產品技術除了同花順自有產品使用,還被許多大型金融機構、運營商其他行業客户使用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.